Clinical Challenges: Is Recalcitrant Atopic Dermatitis Really Comorbid Disease?
Dupilumab failure signals the need for extended patch testing to identify a missed diagnosis
Stay updated with breaking news from Jonathan Silverberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dupilumab failure signals the need for extended patch testing to identify a missed diagnosis
Strong efficacy data for new class of agents in AD, but some apprehension over safety warnings
27.10.2023 - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established eblasakimab’s potential to deliver a monthly ...
(2023-10-24 | NDAQ:ASLN) ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
"This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.